Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAS-004 in MAPK Pathway-driven Advanced Solid Tumors
NCT06299839Phase 1Recruiting
- Sponsor
- Pasithea Therapeutics
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pas-004 in solid tumor (advanced stage) (2 arms), sponsored by Pasithea Therapeutics. Primary endpoints: Dose Limiting Toxicities, Adverse Events and 3 more. Started Feb 2024; status: recruiting.
02
Drugs
pas-004
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06299839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299839.